Clinical Trial Details
| Trial ID: | L0364 |
| Source ID: | NCT04961931 |
| Associated Drug: | Empagliflozin 10 Mg |
| Title: | Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Chronic Kidney Disease stage3 |
| Interventions: | DRUG: Empagliflozin 10 MG |
| Outcome Measures: | Primary: albuminuria, ratio of albumin to creatinine in urine in mg/g, 7 days|serum calcium concentration, serum calcium level in mmol/l, 7 days|urine calcium concentration, level of calcium in urine in mmol/l, 7 days|urine adenosine, adenosine in urine in µmol/mmol creatinine, 7 days|urine phosphorus concetration, serum phosphorus level in mmol/l, 7 days|serum Fibroblast growth factor 23 concentration, serum Fibroblast growth factor 23 level in pg/ml, 7 days|serum parathormone concentration, serum parathormone level in pg/ml, 7 days|serum Klotho concentration, serum Klotho level in ng/ml, 7 days|serum Bone alkaline phosphatase concentration, serum Bone alkaline phosphatase level in µg/l, 7 days|serum 1,25(OH)2D concentration, serum 1,25(OH)2D level in pg/ml, 7 days|serum sclerostin concentration, serum sclerostin level in pmol/l, 7 days|urine phosphorus concetration, phosphorus in urine in mmol/l, 7 days | |
| Sponsor/Collaborators: | Sponsor: Medical University of Lodz |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 45 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION |
| Start Date: | 2019-01-01 |
| Completion Date: | 2021-08-31 |
| Results First Posted: | |
| Last Update Posted: | 2021-07-14 |
| Locations: | Department of Nephrology, Hypertension and Kidney Transplantation, Łódź, 90-153, Poland |
| URL: | https://clinicaltrials.gov/show/NCT04961931 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|